Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption

G. Rozera, I. Abbate, G. D'Offizi, A. Corpolongo, P. Narciso, C. Vlassi, F. Martini, S. Calcaterra, M. R. Capobianchi

Research output: Contribution to journalArticle

Abstract

This study aimed to define clinical and virological parameters associated with spontaneous control of HIV replication in patients having initiated HAART during primary HIV infection, who underwent structured therapy interruption by two protocols with either fixed or HIV viremia-guided scheme. At the end of the protocol all patients were changed to viremia-guided scheme and observed for 12 months (follow-up). Patients maintaining HIV viremia below the indications for resumption of HAART during the follow-up, were defined controllers, those who had to resume HAART were defined non-controllers. The following parameters were examined: pre-interruption therapy duration, CD4+, HIV RNA, proviral DNA, evolution of viral quasispecies. No specific advantage was conferred by either interruption of structured therapy in the proportion of controllers and non-controllers. Pre-HAART and zenith CD4+, pre-therapy interruption, HAART duration, but not pre-HAART HIV RNA, were significantly higher in controllers as compared to non-controllers. HIV RNA levels after the first interruption cycle of therapy were significantly lower in controllers than in non-controllers. Proviral DNA levels were also lower in controllers at this time point. HIV RNA and proviral DNA levels associated with the last interruption of therapy cycle were not different from those associated with the first cycle, and, in spite of multiple waves of virus rebound, very few gag quasispecies variants emerged in each patient. The data suggest that pre-treatment clinical parameters and virological events associated with the first viral rebound are crucial factors in determining the ability to control viral replication after multiple cycles of interruption of treatment.

Original languageEnglish
Pages (from-to)1047-1054
Number of pages8
JournalJournal of Medical Virology
Volume79
Issue number8
DOIs
Publication statusPublished - Aug 2007

Fingerprint

HIV-1
Highly Active Antiretroviral Therapy
HIV
Viremia
RNA
Therapeutics
DNA
Viral DNA
HIV Infections
Viruses

Keywords

  • Genetic heterogeneity
  • HIV-1
  • Provirus
  • Structured therapy interruption
  • Viral load

ASJC Scopus subject areas

  • Virology

Cite this

@article{c097ea1944cb4ebbaa71b9a6fe6dbe41,
title = "Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption",
abstract = "This study aimed to define clinical and virological parameters associated with spontaneous control of HIV replication in patients having initiated HAART during primary HIV infection, who underwent structured therapy interruption by two protocols with either fixed or HIV viremia-guided scheme. At the end of the protocol all patients were changed to viremia-guided scheme and observed for 12 months (follow-up). Patients maintaining HIV viremia below the indications for resumption of HAART during the follow-up, were defined controllers, those who had to resume HAART were defined non-controllers. The following parameters were examined: pre-interruption therapy duration, CD4+, HIV RNA, proviral DNA, evolution of viral quasispecies. No specific advantage was conferred by either interruption of structured therapy in the proportion of controllers and non-controllers. Pre-HAART and zenith CD4+, pre-therapy interruption, HAART duration, but not pre-HAART HIV RNA, were significantly higher in controllers as compared to non-controllers. HIV RNA levels after the first interruption cycle of therapy were significantly lower in controllers than in non-controllers. Proviral DNA levels were also lower in controllers at this time point. HIV RNA and proviral DNA levels associated with the last interruption of therapy cycle were not different from those associated with the first cycle, and, in spite of multiple waves of virus rebound, very few gag quasispecies variants emerged in each patient. The data suggest that pre-treatment clinical parameters and virological events associated with the first viral rebound are crucial factors in determining the ability to control viral replication after multiple cycles of interruption of treatment.",
keywords = "Genetic heterogeneity, HIV-1, Provirus, Structured therapy interruption, Viral load",
author = "G. Rozera and I. Abbate and G. D'Offizi and A. Corpolongo and P. Narciso and C. Vlassi and F. Martini and S. Calcaterra and Capobianchi, {M. R.}",
year = "2007",
month = "8",
doi = "10.1002/jmv.20895",
language = "English",
volume = "79",
pages = "1047--1054",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption

AU - Rozera, G.

AU - Abbate, I.

AU - D'Offizi, G.

AU - Corpolongo, A.

AU - Narciso, P.

AU - Vlassi, C.

AU - Martini, F.

AU - Calcaterra, S.

AU - Capobianchi, M. R.

PY - 2007/8

Y1 - 2007/8

N2 - This study aimed to define clinical and virological parameters associated with spontaneous control of HIV replication in patients having initiated HAART during primary HIV infection, who underwent structured therapy interruption by two protocols with either fixed or HIV viremia-guided scheme. At the end of the protocol all patients were changed to viremia-guided scheme and observed for 12 months (follow-up). Patients maintaining HIV viremia below the indications for resumption of HAART during the follow-up, were defined controllers, those who had to resume HAART were defined non-controllers. The following parameters were examined: pre-interruption therapy duration, CD4+, HIV RNA, proviral DNA, evolution of viral quasispecies. No specific advantage was conferred by either interruption of structured therapy in the proportion of controllers and non-controllers. Pre-HAART and zenith CD4+, pre-therapy interruption, HAART duration, but not pre-HAART HIV RNA, were significantly higher in controllers as compared to non-controllers. HIV RNA levels after the first interruption cycle of therapy were significantly lower in controllers than in non-controllers. Proviral DNA levels were also lower in controllers at this time point. HIV RNA and proviral DNA levels associated with the last interruption of therapy cycle were not different from those associated with the first cycle, and, in spite of multiple waves of virus rebound, very few gag quasispecies variants emerged in each patient. The data suggest that pre-treatment clinical parameters and virological events associated with the first viral rebound are crucial factors in determining the ability to control viral replication after multiple cycles of interruption of treatment.

AB - This study aimed to define clinical and virological parameters associated with spontaneous control of HIV replication in patients having initiated HAART during primary HIV infection, who underwent structured therapy interruption by two protocols with either fixed or HIV viremia-guided scheme. At the end of the protocol all patients were changed to viremia-guided scheme and observed for 12 months (follow-up). Patients maintaining HIV viremia below the indications for resumption of HAART during the follow-up, were defined controllers, those who had to resume HAART were defined non-controllers. The following parameters were examined: pre-interruption therapy duration, CD4+, HIV RNA, proviral DNA, evolution of viral quasispecies. No specific advantage was conferred by either interruption of structured therapy in the proportion of controllers and non-controllers. Pre-HAART and zenith CD4+, pre-therapy interruption, HAART duration, but not pre-HAART HIV RNA, were significantly higher in controllers as compared to non-controllers. HIV RNA levels after the first interruption cycle of therapy were significantly lower in controllers than in non-controllers. Proviral DNA levels were also lower in controllers at this time point. HIV RNA and proviral DNA levels associated with the last interruption of therapy cycle were not different from those associated with the first cycle, and, in spite of multiple waves of virus rebound, very few gag quasispecies variants emerged in each patient. The data suggest that pre-treatment clinical parameters and virological events associated with the first viral rebound are crucial factors in determining the ability to control viral replication after multiple cycles of interruption of treatment.

KW - Genetic heterogeneity

KW - HIV-1

KW - Provirus

KW - Structured therapy interruption

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=34347342653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347342653&partnerID=8YFLogxK

U2 - 10.1002/jmv.20895

DO - 10.1002/jmv.20895

M3 - Article

C2 - 17597482

AN - SCOPUS:34347342653

VL - 79

SP - 1047

EP - 1054

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 8

ER -